retatrutide triple agonist glp-1 gip glucagon #retatrutide is a novel peptide at the receptor, receptor, and receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter https://t.co/duYwW0EcmF Retatrutide is a triple-agonist drug

For example, in the SELECT cardiovascular outcome trial studying people with obesity, the extent of weight loss did not correlate with the effects of the drug to reduce heart attack, stroke, and cardiovascular death . Also, another long-acting GLP-1 therapy, albiglutide, [was] withdrawn from the market owing to modest efficacy for reduction of glucose and body weight in people with T2D

The bottom line: GLP-1 medications are a powerful tool, and the muscle loss concern while valid is manageable with the right approach

Adequate Caloric Intake Some patients on GLP-1s eat too little, leading to reduced sex hormones and fatigue

Ethanol has also been shown to activate SREBP-1c which results in the transcriptional activation of numerous genes involved in lipogenesis

Detailed Protocol

These medications are compounded to provide the same active ingredients as the brand names, ensuring effective treatment without the high costs